

c-IAP2 (58C7) Rabbit mAb



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

Simple Western Blotting 1:1000	Applications: W, W-S, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 70	Source/Isotype: Rabbit IgG	UniProt ID: #Q13489	Entrez-Gene Id: 330
Simple Western™ 1:50 - 1:250 Immunoprecipitation 1:50 - 1:250 Immunoprecipitation 1:50 - 1:250 Immunoprecipitation 1:50 - 1:250 Immunoprecipitation 1:50 - 1:250 Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Species predicted to react based on 100% sequence homology Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val117 of human c-IAP2. Background The inhibitor of apoptosis protein (IAP) family consists of an evolutionarily conserved group of apoptosis inhibitors containing a conserved 70 amino acid BIR (baculovirus inhibitor repeat) domain (1.2). Human members of this family include c-IAP1, c-IAP2, XIAP, survivin, Iivin, and NAIP. Overexpression of IAP family members, particularly survivin and livin, in cancer cell lines and primary tumors suggests an important role for these proteins in cancer progression (3-5). In general, the IAP proteins function through direct interactions to inhibit the activity of several caspases, including caspase-3, caspase-7, and caspase-9 (5,6). In addition, binding of IAP family members to the mitochondrial protein 5mac blocks their interaction with caspase-9, thereby allowing the processing and activation of the caspase (2). 1. Deveraux, Q.L. et al. (1999) **EMBO/17*, 2215-23.** 3. Altieri, D.C. et al. (1999) **Lab Invest 79*, 1327-33.** 4. Tamm, I. et al. (2000) **Clin Cancer Res 6, 1796-803.** 5. Kasof, G.M. and Gomes, B.C. (2001) **Bio Chem 276*, 3238-46.** 6. Deveraux, Q.L. et al. (1997) **Nature 388*, 300-4.** Species Reactivity Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.	Product Usage Information		Application			Dilution	
Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. CalP2 (SBC7) Rabbit mAb detects endogenous levels of total c-IAP2 protein. No cross reactivity was detected on 100% sequence homology Monkey Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val117 of human c-IAP2. Background Monoclonal antibibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val117 of human c-IAP2. The inhibitor of apoptosis protein (IAP) family consists of an evolutionarily conserved group of apoptosis inhibitor scontaining a conserved 70 amino acid BIR (baculovirus inhibitor repeat) domain (1,2). Human members of this family include c-IAP1, c-IAP2, XIAP, survivin, invin, and NAIP. Overexpression of 1AP family members, particularly survivin and livin, in cancer cell lines and primary tumors suggests an important role for these proteins in cancer progression (3-5). In pereral, the IAP proteins function through direct interactions to inhibit the activity of several caspases, including caspase-9, caspase-9, and caspase-9 (5,6). In addition, binding of IAP family members to the mitochondrial protein Smac blocks their interaction with caspase-9, thereby allowing the processing and activation of the caspase (2). Background References 1. Deveraux, Q.L. et al. (1999) Genes Dev 13, 239-52. 2. Deveraux, Q.L. et al. (1998) EMBO/17, 2215-23. 3. Altieri, D.C. et al. (1999) Lab Invest 79, 1327-33. 4. Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803. 5. Kasof, G.M. and Gomes, B.C. (2001) J Biol Chem 276, 3238-46. 6. Deveraux, Q.L. et al. (1997) Nature 388, 300-4. Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot). IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gen			9				
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at ~20°C. Do not aliquot the antibody. Specificity/Sensitivity C-IAP2 (58C7) Rabbit mAb detects endogenous levels of total c-IAP2 protein. No cross reactivity was detected with other family members. Monkey Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val117 of human c-IAP2. The inhibitor of apoptosis protein (IAP) family consists of an evolutionarily conserved group of apoptosis inhibitors containing a conserved 70 amino acid BIR (baculovirus inhibitor repeat) domain (1,2). Human members of this family include c-IAP1, c-IAP2, XIAP, survivin, livin, and NAIP. Overexpression of IAP family members, particularly survival and livin, in cancer cell lines and primary tumors suggests an important role for these proteins in cancer progression (3-5). In general, the IAP proteins function through direct interactions to inhibit the activity of several caspases, including caspase-3, caspase-7, and caspase-9 (5,6). In addition, binding of IAP family members to the mitochondrial protein Smac blocks their interaction with caspase-9, thereby allowing the processing and activation of the caspase (2). Background References Background References 1. Deveraux, Q.L. and Reed, J.C. (1999) Genes Dev 13, 239-52. 2. Deveraux, Q.L. et al. (1999) Lab Invest 79, 1327-33. 3. Alteri, D.C. et al. (1999) Lab Invest 79, 1327-33. 4. Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803. 5. Kasof, G.M. and Gomes, B.C. (2001) J Biol Chem 276, 3238-46. 6. Deveraux, Q.L. et al. (1997) Nature 388, 300-4. Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot). IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.			•				
O.02% sodium azide. Store at ~20°C. Do not aliquot the antibody. Specificity/Sensitivity c-IAP2 (S8C7) Rabbit mAb detects endogenous levels of total c-IAP2 protein. No cross reactivity was detected with other family members. Monkey Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val117 of human c-IAP2. The inhibitor of apoptosis protein (IAP) family consists of an evolutionarily conserved group of apoptosis inhibitors containing a conserved 70 amino acid BIR (baculovirus inhibitor repeat) domain (1,2). Human members of this family include c-IAP1, c-IAP2, XIAP, survivin, livin, and NAIP. Overexpression of IAP family members, particularly avivin and livin, in cancer cell lines and primary tumors suggests an important role for these proteins in cancer progression (3-5). In general, the IAP proteins function through direct interactions to inhibit the activity of several caspases, including caspase-3, caspase-7, and caspase-9 (5,6). In addition, binding of IAP family members to the mitochondrial protein Smac blocks their interaction with caspase-9, thereby allowing the processing and activation of the caspase (2). Background References Background References 1. Deveraux, Q.L. and Reed, J.C. (1999) Genes Dev 13, 239-52. 2. Deveraux, Q.L. et al. (1998) EMBO/17, 2215-23. 3. Altieri, D.C. et al. (1998) EMBO/17, 2215-23. 3. Altieri, D.C. et al. (1999) Lab Invest 79, 1327-33. 4. Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803. 5. Kasof, G.M. and Gomes, B.C. (2001) J Biol Chem 276, 3238-46. 6. Deveraux, Q.L. et al. (1997) Nature 388, 300-4. Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot). IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.			Immunoprecipitation			1:100	
Species predicted to react based on 100% sequence homology Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val117 of human c-IAP2. Background The inhibitor of apoptosis protein (IAP) family consists of an evolutionarily conserved group of apoptosis inhibitors containing a conserved 70 amino acid BIR (baculovirus inhibitor repeat) domain (1,2). Human members of this family include c-IAP1, c-IAP2, XIAP, survivin, livin, and NAIP. Overexpression of IAP family members, particularly survivin and livin, in cancer cell lines and primary tumors suggests an important role for these proteins in cancer progression (3-5). In general, the IAP proteins function through direct interactions to inhibit the activity of several caspases, including caspase-3, caspase-7, and caspase-9 (5,6). In addition, binding of IAP family members to the mitochondrial protein Smac blocks their interaction with caspase-9, thereby allowing the processing and activation of the caspase (2). Background References 1. Deveraux, Q.L. and Reed, J.C. (1999) Genes Dev 13, 239-52. 2. Deveraux, Q.L. et al. (1998) Lab Invest 79, 1327-33. 3. Altieri, D.C. et al. (1999) Lab Invest 79, 1327-33. 4. Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803. 5. Kasof, G.M. and Gomes, B.C. (2001) J Biol Chem 276, 3238-46. 6. Deveraux, Q.L. et al. (1997) Nature 388, 300-4. Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot). Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.	Storage						
Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val117 of human c-IAP2. The inhibitor of apoptosis protein (IAP) family consists of an evolutionarily conserved group of apoptosis inhibitors containing a conserved 70 amino acid BIR (baculovirus inhibitor repeat) domain (1,2). Human members of this family include c-IAP1, C-IAP2, XIAP, survivin, livin, and NAIP. Overexpression of IAP family members, particularly survivin and livin, in cancer cell lines and primary tumors suggests an important role for these proteins in cancer progression (3-5). In general, the IAP proteins function through direct interactions to inhibit the activity of several caspases, including caspase-3, caspase-7, and caspase-9 (5,6). In addition, binding of IAP family members to the mitochondrial protein Smac blocks their interaction with caspase-9, thereby allowing the processing and activation of the caspase (2). Background References 1. Deveraux, Q.L. et al. (1998) **EMBO** J17, 2215-23. 3. Altieri, D.C. et al. (1999) **Lab Invest 79, 1327-33. 4. Tamm, I. et al. (2000) **Clin Cancer Res 6, 1796-803. 5. Kasof, G.M. and Gomes, B.C. (2001) **Biol Chem 276, 3238-46. 6. Deveraux, Q.L. et al. (1997) **Nature 388, 300-4. **Species Reactivity** Species reactivity is determined by testing in at least one approved application (e.g., western blot). Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.	Specificity/Sensitivity						
The inhibitor of apoptosis protein (IAP) family consists of an evolutionarily conserved group of apoptosis inhibitors containing a conserved 70 amino acid BIR (baculovirus inhibitor repeat) domain (1,2). Human members of this family include c-IAP1, c-IAP2, XIAP, survivin, livin, and NAIP. Overexpression of IAP family members, particularly survivin and livin, in cancer cell lines and primary tumors suggests an important role for these proteins in cancer progression (3-5). In general, the IAP proteins function through direct interactions to inhibit the activity of several caspases, including caspase-3, caspase-7, and caspase-9 (5,6). In addition, binding of IAP family members to the mitochondrial protein Smac blocks their interaction with caspase-9, thereby allowing the processing and activation of the caspase (2). Background References 1. Deveraux, Q.L. and Reed, J.C. (1999) Genes Dev 13, 239-52. 2. Deveraux, Q.L. et al. (1998) EMBO J 17, 2215-23. 3. Altieri, D.C. et al. (1999) Lab Invest 79, 1327-33. 4. Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803. 5. Kasof, G.M. and Gomes, B.C. (2001) J Biol Chem 276, 3238-46. 6. Deveraux, Q.L. et al. (1997) Nature 388, 300-4. Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot). Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.	Species predicted to react based on 100% sequence homology		Monkey				
apoptosis inhibitors containing a conserved 70 amino acid BIR (baculovirus inhibitor repeat) domain (1,2). Human members of this family include c-IAP1, c-IAP2, XIAP, survivin, livin, and NAIP. Overexpression of IAP family members, particularly survivin and livin, in cancer cell lines and primary tumors suggests an important role for these proteins in cancer progression (3-5). In general, the IAP proteins function through direct interactions to inhibit the activity of several caspases, including caspase-3, caspase-7, and caspase-9 (5,6). In addition, binding of IAP family members to the mitochondrial protein Smac blocks their interaction with caspase-9, thereby allowing the processing and activation of the caspase (2). Background References 1. Deveraux, Q.L. and Reed, J.C. (1999) Genes Dev 13, 239-52. 2. Deveraux, Q.L. et al. (1998) EMBO J 17, 2215-23. 3. Altieri, D.C. et al. (1999) Lab Invest 79, 1327-33. 4. Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803. 5. Kasof, G.M. and Gomes, B.C. (2001) J Biol Chem 276, 3238-46. 6. Deveraux, Q.L. et al. (1997) Nature 388, 300-4. Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot). IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.	Source / Purification						
2. Deveraux, Q.L. et al. (1998) EMBO J 17, 2215-23. 3. Altieri, D.C. et al. (1999) Lab Invest 79, 1327-33. 4. Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803. 5. Kasof, G.M. and Gomes, B.C. (2001) J Biol Chem 276, 3238-46. 6. Deveraux, Q.L. et al. (1997) Nature 388, 300-4. Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot). Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.	Background		apoptosis inhibitors containing a conserved 70 amino acid BIR (baculovirus inhibitor repeat) domain (1,2). Human members of this family include c-IAP1, c-IAP2, XIAP, survivin, livin, and NAIP. Overexpression of IAP family members, particularly survivin and livin, in cancer cell lines and primary tumors suggests an important role for these proteins in cancer progression (3-5). In general, the IAP proteins function through direct interactions to inhibit the activity of several caspases, including caspase-3, caspase-7, and caspase-9 (5,6). In addition, binding of IAP family members to the mitochondrial protein Smac blocks their interaction with caspase-9, thereby allowing the processing				
Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.	Background References		 Deveraux, Q.L. et al. (1998) EMBO J 17, 2215-23. Altieri, D.C. et al. (1999) Lab Invest 79, 1327-33. Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803. Kasof, G.M. and Gomes, B.C. (2001) J Biol Chem 276, 3238-46. 				
TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.	Species Reacti	vity	Species reactivity is det	ermined by testing	g in at least one approv	ed application (e.g.,	western blot).
Applications Key W: Western Blotting W-S: Simple Western™ IP: Immunoprecipitation	Western Blot Buffer						
	Applications Key		W: Western Blotting W-S: Simple Western [™] IP: Immunoprecipitation				

Cross-Reactivity Key

H: Human

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless

separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.